MediWound director Stephen Wills files Form 3

MediWound Ltd. filed an initial ownership report for director Stephen T. Wills, detailing his existing holdings in ordinary shares and stock options.

Rhea-AI Filing Summary

MediWound Ltd. filed an initial ownership report for director Stephen T. Wills, detailing his existing holdings in ordinary shares and stock options. The filing lists multiple stock option awards on ordinary shares with exercise prices ranging from 11.8850 to 37.5200 and expiration dates between 2029 and 2036. It also notes ordinary shares underlying RSUs and an option grant made on March 4, 2026 that vest 100% on the one-year anniversary of the grant date, showing his current equity-based alignment with the company.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider WILLS STEPHEN T

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Ordinary shares	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 56,362 contracts (Direct); Ordinary shares — 10,429 shares (Direct)

Footnotes (2)

1. F1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
2. F2. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does MediWound (MDWD) disclose in Stephen T. Wills’ Form 3 filing?

The Form 3 lists Stephen T. Wills’ existing holdings in MediWound equity. It details ordinary shares and several stock option grants on ordinary shares, including exercise prices, expiration dates, and specific vesting terms for awards granted on March 4, 2026.

Does Stephen T. Wills buy or sell MediWound (MDWD) shares in this Form 3?

No buy or sell transactions are reported in this Form 3. The entries are classified as holdings, and the transaction summary shows zero buys, zero sells, and 10 holding entries, indicating this is an initial snapshot of existing positions.

What stock options are reported for Stephen T. Wills in MediWound (MDWD)?

The filing lists several stock option awards to buy MediWound ordinary shares. Each option series shows an exercise price, underlying ordinary shares, and expiration dates ranging from 2029 to 2036, outlining his long-dated incentive exposure to the company’s equity.

What are the vesting terms of the March 4, 2026 MediWound (MDWD) grants to Stephen T. Wills?

Footnotes state that RSUs and options granted on March 4, 2026 vest 100% on the one-year anniversary of the grant date. This means those awards become fully vested after one year, subject to the stated terms, strengthening his near-term equity incentives.

What ordinary share holdings does Stephen T. Wills report in MediWound (MDWD)?

The Form 3 shows direct ownership of MediWound ordinary shares, with separate rows for these positions. Some ordinary shares are described in a footnote as underlying RSUs that were granted on March 4, 2026 and vest fully one year after that grant date.

How does the Form 3 characterize Stephen T. Wills’ ownership type in MediWound (MDWD)?

All listed positions are coded as direct ownership. Each row uses a direct ownership code and does not reference any trusts or entities in the nature-of-ownership field, indicating the holdings are reported as directly owned by Stephen T. Wills.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WILLS STEPHEN T

(Last) (First) (Middle)

C/O MEDIWOUND LTD.,

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	9,679	D
Ordinary shares(1)	750	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	03/24/2020	03/24/2029	Ordinary shares	2,857	$34.4281	D
Stock Option (right to buy ordinary shares)	06/29/2021	06/29/2030	Ordinary shares	14,285	$12.25	D
Stock Option (right to buy ordinary shares)	06/15/2022	06/15/2031	Ordinary shares	3,214	$37.52	D
Stock Option (right to buy ordinary shares)	05/16/2023	05/16/2032	Ordinary shares	10,714	$14.42	D
Stock Option (right to buy ordinary shares)	05/31/2024	05/30/2033	Ordinary shares	5,900	$11.885	D
Stock Option (right to buy ordinary shares)	02/26/2025	02/26/2034	Ordinary shares	7,542	$12.729	D
Stock Option (right to buy ordinary shares)	02/11/2026	02/11/2035	Ordinary shares	5,600	$18.54	D
Stock Option (right to buy ordinary shares)	(2)	03/04/2036	Ordinary shares	6,250	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)